Table 1.
Baseline demographic and treatment characteristics by HIV status of women with FIGO 2009 stage IIIB cervical cancer in Botswana
| Characteristic | HIV seropositive (n=118 (63.1%)) | HIV seronegative (n=69 (36.9%)) | P value |
|---|---|---|---|
| Age (years) | |||
| Median (IQR) | 46 (39–50) | 61 (49–70) | <0.01 |
| Weight (kg)* | |||
| <60 | 42 (42) | 32 (57) | 0.08 |
| ≥60 | 57 (58) | 24 (43) | |
| Median (IQR) 59 (50–75) | |||
| Body mass index (kg/m2)* | |||
| ≤20 | 31 (34) | 11 (22) | 0.13 |
| >20 | 61 (66) | 40 (78) | |
| Median (IQR) 23 (19–28) | |||
| Tumor histology | |||
| SCC | 102 (86) | 63 (91) | 0.32 |
| Non-SCC | 16 (14) | 6 (9) | |
| History of tuberculosis | |||
| Yes | 15 (13) | 2 (3) | 0.02 |
| No | 103 (87) | 67 (97) | |
| CD4 count (cells/mL)* | |||
| <400 | 62 (56) | N/A | N/A |
| ≥400 | 49 (44) | ||
| Median (IQR) 445 (319–657) | |||
| Viral load (cells/mL)* | |||
| ≥400 | 11 (13) | N/A | N/A |
| <400 | 75 (87) | ||
| Hemoglobin (g/dL)* | |||
| <12 | 93 (86) | 46 (72) | 0.02 |
| ≥12 | 15 (14) | 18 (28) | |
| Median (IQR) 10.2 (8.7–11.5) | |||
| Creatinine (μmol/L)* | |||
| >90 | 15 (13) | 16 (25) | 0.05 |
| ≤90 | 99 (87) | 49 (75) | |
| Median (IQR) 65 (51–84) | |||
| KPS* | |||
| 40–80 | 32 (27) | 22 (32) | 0.51 |
| 90–100 | 85 (73) | 47 (68) | |
| Median (IQR) 90 (40–100) | |||
| ART | |||
| Yes | 110 (93) | N/A | N/A |
| No | 8 (7) | ||
| Treatment year | |||
| 2013–2015 | 42 (36) | 31 (45) | 0.21 |
| 2016–2018 | 76 (64) | 38 (55) | |
| TTT*† (months) | |||
| >3 months | 58 (60) | 32 (68) | 0.37 |
| ≤3 months | 38 (40) | 15 (32) | |
| Median (IQR) 3.4 (2.3–5.0) | |||
| Total RT dose, EQD2 (Gy) | |||
| ≥80 | 43 (36) | 22 (32) | 0.528 |
| <80 | 75 (64) | 47 (68) | |
| Median (IQR) 68 (55–74) | |||
| RT course length* (weeks) | |||
| <7 | 64 (54) | 42 (62) | 0.318 |
| ≥7 | 54 (46) | 26 (38) | |
| Median (IQR) 47 days (39–52) | |||
| Brachytherapy | |||
| Yes | 78 (66) | 42 (61) | 0.47 |
| No | 40 (34) | 27 (39) | |
| EBRT boost | |||
| Yes | 37 (31) | 21 (30) | 0.90 |
| No | 81 (69) | 48 (70) | |
| CRT | |||
| Yes | 58 (49) | 32 (46) | 0.71 |
| No | 60 (51) | 37 (54) | |
| Treatment response*‡ | |||
| Complete | 49 (48) | 31 (57) | 0.24 |
| Non-complete | 54 (52) | 23 (43) | |
*
Data are incomplete due to missing individual patient data.
†
TTT is defined as time from pathological diagnosis to initiation of treatment.
‡
Treatment response is defined as clinically apparent tumor regression on examination.
ART, antiretroviral therapy; BMI, body mass index; CRT, chemoradiation therapy; EBRT, external beam radiation therapy; EQD2, radiobiological equivalent dose; FIGO, International Federation of Gynecology and Obstetrics; HIV, human immunodeficiency virus; KPS, Karnofsky Performance Score; RT, radiation therapy; SCC, squamous cell carcinoma.;